Refine by
Disease Reported In Several Articles & Analysis: Older
136 news found
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, is excited to announce the launch of its new line of H5N1 Antibodies and Antigens to support cutting-edge research on this highly pathogenic influenza A virus subtype. These innovative products offer researchers and scientists invaluable tools for studying and combating the H5N1 influenza virus. ...
Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) are major global health threats. Their interaction worsens disease severity, as HIV reduces CD4+ T cells, making individuals more vulnerable to TB. Despite progress, an effective animal model that mimics human immune response during HIV/TB co-infection has been lacking, hindering treatment and vaccine development. Bohorguez et al. ...
Recent advances in the fight against severe acute inflammatory lung diseases, including COVID-19, have revealed a promising new approach to treating pulmonary hyperinflammation and long-term lung damage such as fibrosis. A groundbreaking study has developed a first-in-class, carbohydrate-coupled inhibitor of microRNA-21 (RCS-21), which shows significant potential as a therapeutic agent. This ...
Alfa Cytology, a premier contract research organization, recently launched its full-scale pancreatic cancer research services with robust platforms, powerful analytics, and cross-platform collaborations. Pancreatic cancer (PC) is a severe disease that is difficult to diagnose in the early stages due to its complex and hidden nature. Studies found that the incidence rate of PC has been ...
The multi-target research and development partnership will focus on severe skin diseases The collaboration leverages etherna’s proprietary mRNA and lipid nanoparticle (LNP) technology with Almirall’s expertise in the dermatology space In addition to upfront and technology access payments, etherna is eligible to receive €300 million in development and commercial ...
ByeTheRNA
Stem cell therapy is a groundbreaking field in the pharmaceutical industry, offering powerful tools for treating severe diseases such as cancer. The genetic manipulations involved in this process, however, necessitate stringent regulations to ensure sterility and safety. In 2017, the Food and Drug Administration (FDA) took significant steps towards regulating stem cell therapy, marking a pivotal ...
As several gene therapy approvals for rare disease treatment gain steam in 2023, a comprehensive set of gene therapy development solutions is released to pave richer avenues for rare disease research. This path-breaking move sees the integration of cutting-edge technology with state-of-art research facilities to amplify the possibilities of devising effective remedies for rare diseases. Rare ...
Vitalograph, a global leader in the development and production of respiratory diagnostic solutions and clinical trial services, has launched the Vitalograph tremoflo® C-100 at this year’s ATS International Conference, taking place in Washington. ...
Ultrasound HIFU beauty machine is a non-surgical skin tightening treatment, that uses medical aesthetic focused ultrasound technology to bypass the epidermis and heat the energy to 65-70°C and condense it into a large number of extremely fine hot spots. It is a one-time treatment with natural and progressive results that last from one to two years (results vary from person to person), with ...
Our latest publication in Cardiovascular Engineering and Technology showcases the feasibility and functionality of our VCAST technology, a patented, AI-based medical system developed for non-invasive, clinical quantitative and qualitative analysis of CT-scan data, to assess the hemodynamic significance of coronary artery atherosclerotic stenosis. Using a ...
European Commission granted approval for a label update to extend the indication of Kerendia™ to early stages of chronic kidney disease (CKD) associated with type 2 diabetes (T2D) and to include findings from the Phase III FIGARO-DKD cardiovascular (CV) outcomes study FIGARO-DKD included approximately 7,400 patients across a broad range of disease severity, including stages 1-4 CKD ...
ByBayer AG
Iterative Scopes, a pioneer in precision-medicine technologies for gastroenterology, announced today that it has partnered with One GI®, a gastroenterology management services organization (MSO), to bring its AI Recruitment (AIR) technology to One GI’s clinical research. Initially, One GI® will use AIR at Gastro One, one of One GI’s clinical research sites in Memphis, ...
CHMP opinion is based on the results from the Phase III FIGARO-DKD cardiovascular (CV) outcomes study in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), which included approximately 7,400 patients across a broad range of disease severity, including stages 1-4 CKD associated with T2D The positive data from FIGARO-DKD demonstrated that finerenone significantly reduced the ...
ByBayer AG
BRIM Biotechnology, Inc. (“BRIM,” TPEx 6885) is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for BRM424 in the treatment of neurotrophic keratitis (NK), a rare degenerative eye disease which causes very severe cornea damage and can lead to loss of sight. Dr. Haishan Jang, Chairwoman and CEO of BRIM Biotechnology, ...
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the Zephyr® Endobronchial Valve for treating severe COPD/emphysema patients following a positive recommendation by Pharmaceuticals and Medical Devices Agency (PMDA). ...
Analysis by Airfinity shows between 1.3 and 2.1 million lives could be at risk if China lifts its zero-COVID policy given low vaccination and booster rates as well as a lack of hybrid immunity. Airfinity’s risk analysis uses cumulative peak cases and deaths from Hong Kong's BA.1 wave as a proxy for mainland China. Hong Kong took a zero-COVID approach for the first two years of the ...
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the 34th Annual Piper Sandler Healthcare Conference in New York on Wednesday, November 30, 2022, at 11:30 AM PT / 2:30 PM ET. A live and archived webcast of the presentation will be available ...
Antibodies (immunoglobulins) are a key component of the mammalian immune response and are increasingly of interest as a means of therapy for several diseases. In fact, there are over 100 monoclonal antibodies that have been approved as drugs1. Despite this apparent success, there are issues with biopharmaceutical antibody research and development – not least the cost of goods. Although it ...
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in two upcoming investor conferences in New York. Pulmonx management is scheduled to participate in a fireside chat at the Stifel Healthcare Conference on Wednesday, November 16, 2022, at 8:00AM ET. Interested ...
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that the U.S. Food and Drug Administration (FDA) has granted the company Fast Track designation for ITM-11 (n.c.a. 177Lu-edotreotide), an investigational radiopharmaceutical for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). ITM-11 is being evaluated as a Targeted ...